DH was approved by the Food and Drug Administration (FDA) as early as 1996 for the treatment of AD, with the inhibition of AChE activity, ensuing a rise in the Ach level and an improvement in AD as its suggestive mechanism [10]. This evidence concerns the gene FGFR3 and Alzheimer disease.